This year, the interplay between A-shares and Hong Kong stocks has intensified significantly. On one front, prominent companies in the A-share market, specializing in cutting-edge technology and consumer manufacturing, are increasingly opting to list H-shares on the Hong Kong Stock Exchange, emerging as a pivotal force in Hong Kong's IPO landscape. Concurrently, Hong Kong's science and technology innovation firms, spanning AI, robotics, and innovative pharmaceuticals, are expediting their efforts to re-enter the A-share market. Leveraging institutional benefits, avenues for loss-making enterprises to relist have been paved. Tian Lihui, a finance professor at Nankai University, highlighted the ongoing expansion of the 'A+H' model. This reciprocal flow dismantles market barriers, fosters the deep integration of regulatory frameworks and information disclosure norms, and facilitates the bidirectional transfer of pricing influence, thereby narrowing cross-border valuation disparities and boosting the overall pricing efficiency of Chinese assets. This not only solidifies the standing of Chinese assets in global allocation but also sets a tangible precedent for constructing a modern capital market system imbued with Chinese characteristics. The market broadly concurs that, within the current policy landscape, dual listings on the 'A+H' platforms are poised to enter a new era of normalized growth.